Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Translate Bio, Inc. TBIO
$37.36
+$751.21 (2 010.73%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1104234763.00000000
-
week52high
37.99
-
week52low
12.50
-
Revenue
27435000
-
P/E TTM
-23
-
Beta
0.00000000
-
EPS
-1.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
21 мар 2023 г. в 20:30
Описание компании
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Neutral | Neutral | 04 авг 2021 г. |
| William Blair | Market Perform | Outperform | 03 авг 2021 г. |
| SVB Leerink | Market Perform | Market Perform | 03 авг 2021 г. |
| Roth Capital | Buy | Buy | 26 июл 2021 г. |
| SVB Leerink | Market Perform | Market Perform | 10 мая 2021 г. |
| Keybanc | Overweight | Overweight | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Demetri George | D | 0 | 20000 | 14 сент 2021 г. |
| BAUPOST GROUP LLC/MA | D | 0 | 18044239 | 14 сент 2021 г. |
| Meyer Robert J. | D | 0 | 18900 | 14 сент 2021 г. |
| Sutherland Everett Rand | D | 0 | 300000 | 14 сент 2021 г. |
| Hughes Owen | D | 0 | 29860 | 14 сент 2021 г. |
| FORMELA JEAN FRANCOIS | D | 0 | 2055063 | 14 сент 2021 г. |
| Beckman Daniella | D | 0 | 67995 | 14 сент 2021 г. |
| Burgess Paul D. | D | 0 | 71833 | 14 сент 2021 г. |
| Plenge Robert M | D | 0 | 37800 | 14 сент 2021 г. |
| Smith Brendan | D | 0 | 201800 | 14 сент 2021 г. |
Новостная лента
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
GlobeNewsWire
27 апр 2023 г. в 16:05
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
Seeking Alpha
25 мар 2023 г. в 10:28
Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
21 мар 2023 г. в 19:04
Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio to Present at Festival of Biologics Conference
GlobeNewsWire
16 мар 2023 г. в 06:00
Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions”